1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bacil Pharma Ltd

Bacil Pharma Ltd

BBSE:BACPHAR
19.98
INR
-0.46
(-2.25%)
0.48EPS
84.03P/E
558.67MMarket Cap
Bacil Pharma Ltd
BSE:BACPHAR
(Bombay Stock Exchange)

Recent

price

19.98

P/E

ratio

84.03

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
0.01
0.72
1.81
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.01
0.07
-0.04
-0.19
-0.05
-0.11
- -
-6.37
-0.58
-0.54
-0.41
-6.55
-0.17
-0.1
0.28
1.11
0.48
Basic EPS, GAAP
0.03
-0.51
0.12
0.09
0.29
-8.5
-0.01
1.93
-0.51
-0.65
-0.68
-6.8
-0.25
- -
0.28
0.51
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
11.18
11.26
11.22
11.03
10.98
10.86
10.93
3.8
3.24
2.35
2.36
2.08
1.87
2.06
17.72
17.29
- -
Book Value per Share
11.18
6.08
5.96
5.66
5.51
10.86
10.93
3.8
3.24
2.35
2.36
2.08
1.87
2.06
17.72
17.29
- -
Tangible Book Value per Share
6
6
6
6
6
6
6
6
6
6
6
6
6
6
14
14
14
Basic Weighted Avg Shares
- -
5
11
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-814.8
9.51
-3.06
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
- -
-1
- -
-38
-3
-3
-2
-39
-1
-1
4
16
7
Net Income, GAAP
- -
15.45
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.85
- -
- -
Effective Tax Rate (%)
-103.09
9.69
-2.21
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
3
6
5
4
3
-3
-2
-14
-21
-24
-24
3
2
-1
27
-8
- -
Working Capital
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
66
66
66
65
65
64
64
22
19
14
14
12
11
12
254
248
- -
Total Equity
- -
0.65
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1.38
- -
- -
Return on Invested Capital (%)
- -
0.65
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.01
- -
- -
Return on Capital (%)
-0.09
0.67
-0.35
-1.67
-0.49
-1.04
-0.03
-86.49
-16.51
-19.12
-17.22
-295.12
-8.77
-5.11
3.03
6.19
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
498
685
559

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
18
- -
Cash, Cash Equivalents & STI
- -
6
- -
Accounts Receivable, Net
- -
12
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
26
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
187.56%
396.39%
-2.43%
Free Cash Flow
-2,681.71%
-2,626.06%
77.54%
Net Income, GAAP
18,224.15%
174.92%
284.92%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.06
0.82
-0.1
0.03
0.28
2026
0.48
0.01
0.03
0.44
1.11
2027
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bacil Pharma Limited operates in the development, manufacturing, and distribution of a diverse array of pharmaceutical and botanical products. Its comprehensive portfolio includes a variety of tablets, capsules, injectables, ointments, and specialized medicinal items. The company maintains its production facility in Lote-Parshuram, which is also equipped for processing herbal extracts and drug intermediates. Established on May 8, 1987, the firm's main office is located in Mumbai, India.